Recording: PARP inhibitors in prostate cancer. Part 1
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | Not approved |
| Duration | Approx. 60 minutes |
Moderator(s)
Prof. Dr. D. Tilki (DE)
Presenter(s)
Prof. B. Tombal (BE)
Prof. Dr. H.G. Van Der Poel (NL)
PARP inhibitors in prostate cancer treatment is still a relatively new topic for most urologists. With this PARPi curriculum we offer urologists an educational programme addressing the following learning objectives:
1. Understanding the rationale for PARPi combinations as potential PCa treatments
2. Getting more insights on patient selection/identification for potential treatment with PARPi combinations
3. Learn the latest developments by discussing ongoing clinical trial design exploring PARPi combinations in Prostate Cancer
In a series of webinars we will tackle its role in prostate cancer treatment, discussing the latest evidence and a practical guide in how to use it in your daily practice.